Zynerba is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.
Investor deep dive
Zynerba’s CBD gel to treat Fragile X syndrome ventures where Big Pharma fears to tread
Zynerba Pharmaceuticals anticipates data in late 2019 for its phase 3 cannabinoid drug
Quick facts: Zynerba Pharmaceuticals
Price: 8.08 USD
Market Cap: $187.44 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE